<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367574</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 251</org_study_id>
    <nct_id>NCT01367574</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction</brief_title>
  <official_title>A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous
      methylnaltrexone to be conducted in patients with advanced medical illness and poorly
      controlled opioid induced constipation. Patients will be randomized to one of three fixed
      dose levels of SC MNTX.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects who have a bowel movement within four hours of dosing</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>To access the efficacy of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subject with Adverse Events</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>To access the tolerability of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Bowel Dysfunction</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC MNTX</intervention_name>
    <description>Dose 1</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC MNTX</intervention_name>
    <description>Dose 2</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC MNTX</intervention_name>
    <description>Dose 3</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have advanced medical illness (cancer, HIV, etc) and be receiving palliative care

          2. Must be on opioid medication for at least 2 weeks with no expectation of significant
             change in regimen

          3. Must have constipation

          4. Must be 18 yrs or older

        Exclusion Criteria:

          1. Concurrent use of medications other than opioids which might interfere with
             gastrointestinal motility

          2. Patients who received any experimental drug in the last 30 days

          3. Patients with active peritoneal cancer (ovarian, etc.)

          4. Patients with active diverticulitis or diverticulosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, M.D.</name_title>
    <organization>Progenics Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Opioid-induced bowel dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

